Listing & Compliance Notices

AIB Acquisition Corp received a nasdaq deficiency notice notice regarding other (rules 5450(a)(2)).

“ent (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that the Company’s public holders of its Class A ordinary shares (“Public Holders”) were below the 400 Public Holders minimum requirement for continued inclusion on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(2) (the “Public Holders Requirement”). The notifications received have no immediate effect on the Company’s Nasdaq listing. The Nasdaq rules provide the Company 45 calendar days to submit a plan to regain compliance and a compliance period of up to 180 calendar days in which to evidence comp”

Bird Global, Inc. received a nyse delisting notice notice regarding market value (rules 802.01B).

“23. Beginning September 25, 2023, trading of the Securities was suspended. NYSE Regulation’s staff decided to delist the Securities because the Company failed to maintain an average global market capitalization of at least $15,000,000 over a consecutive 30 trading day period, as required by Section 802.01B of the NYSE Listed Company Manual. The Company has a right to appeal this determination, provided that it files a written request for such review within ten business days after receiving the Notice. The Company’s board of directors (the “Board”) intends to appeal the NYSE’s determination to”

MOBIX LABS, INC received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

“y the Company, which indicated that for the previous 30 consecutive business days, the minimum Market Value of Listed Securities (“MVLS”) for the Company’s ordinary shares was below the $35 million minimum MVLS requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”) and that the Company had until September 19, 2023 to regain compliance. The Notice states that the Company has not regained compliance with the MVLS Rule within the required 180-day period and that the ordinary shares and the other listed securities of the Company (Nasda”

Coliseum Acquisition Corp. received a nasdaq delisting notice notice regarding shareholders (rules 5550(a)(3)).

“n to file periodic reports with the Securities and Exchange Commission under applicable federal securities laws. The Company intends to appeal Nasdaq’s delisting determination by requesting a hearing before a Hearings Panel (the “ Panel ”), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. Such request would automatically stay the suspension of the Company’s securities pending the Panel’s decision. Forward Looking Statements Certain information contained in this report consists of forward-looking statements within the meaning of the Private Securities Litigation Refo”

Edoc Acquisition Corp. received a nasdaq deficiency notice notice regarding other (rules 5550(a)(3)).

“September 25, 2023, EDOC Acquisition Corp., an exempted company incorporated in the Cayman Islands (the “Company”), received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that the Company no longer meets the minimum 300 public holders requirement for The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(3) (the “Minimum Public Holders Requirement”). The notification received has no immediate effect on the Company’s Nasdaq listing. In accordance with Nasdaq rules, the Company has 45 calendar d”

Galera Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).

“September 25, 2023, Galera Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that the Company is no longer in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) of $15,000,000 required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(b)(2)(C) (the “Minimum MVPHS Requirement”). The Notice has no effect at this time on the listing of the Company’s common stock, par value $0.001 per share (“Common Stock”), which continues to trade on The Nasd”

TuHURA Biosciences, Inc./NV received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“September 20, 2023, Kintara Therapeutics, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). In the Company’s Annual Report on Form 10-K for the year ended June 30, 2023, the Company reported stockholders’ equity of $73”

Histogen Inc. received a nasdaq delisting notice notice regarding other (rules 5101).

“September 26, 2023 by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Staff’s determination that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101, trading of the Company’s common stock will be suspended from trading at the opening of business on October 5, 2023 unless the Company timely requests a hearing before a Nasdaq Hearings Panel to address the deficiencies and present a plan to regain compliance. The Company does not plan to request a hearing and, therefore, expects that trading in the”

INSEEGO CORP. received a nasdaq delisting notice notice regarding minimum bid price.

“September 21, 2023, the Company received a letter from Nasdaq stating that the Company had not regained compliance with the Minimum Bid Price Requirement by the required Compliance Date and, as a result, the Company’s Common Stock is subject to delisting. The Company submitted a hearing request to Nasdaq to appeal the delisting determination on September 22, 2023, which has automatically stayed the delisting of the Company’s Common Stock from The Nasdaq Global Select Market pending a decision from a Nasdaq listing qualifications hearings panel (the “Panel”) decision. In response, Nasdaq set a”

Cardio Diagnostics Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(2), 5810(c)(3)(A), 5810(c)(3)(H)).

“ilure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 21, 2023, Cardio Diagnostics Holdings, Inc. (the “Company”) received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is no longer in compliance with Nasdaq Listing Rule 5450(a)(2), because the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days (the “Notice”). The Notice has no immediate effect on the listing or trading of the Company’s common stock or warrants on the Nasdaq Capital Market. In accordance w”

Unicycive Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“September 19, 2023, Unicycive Therapeutics, Inc. (the “Company”) received written notification (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the market value of the Company’s Common Stock (the “Common Stock”), had closed below the minimum $35 million requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “Minimum Market Value Requirement”). The Notice has no immediate effect on the listing or trading of the Common Stock on the N”

Unicycive Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“September 19, 2023, Unicycive Therapeutics, Inc. (the “Company”) received written notification (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the market value of the Company’s Common Stock (the “Common Stock”), had closed below the minimum $35 million requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “Minimum Market Value Requirement”). The Notice has no immediate effect on the listing or trading of the Common Stock on the N”

InMed Pharmaceuticals Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“September 19, 2023, the Company received written notice from the listing qualifications department staff of The Nasdaq Capital Market (“Nasdaq”) notifying it that the average closing bid price of the Company's common shares over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5550(a)(2). In accordance with applicable Nasdaq procedures, the Company has a period of 180 calendar days following the receipt of the written notice mentioned above to cure the deficiency and regain compliance. The no”

Spyre Therapeutics, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“September 22, 2023, the Company received a letter (the “Compliance Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had regained compliance with the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Compliance Letter noted that (1) the Company’s common stock, par value $0.0001 per share (the “Common Stock”), had a closing bid price of at least $1.00 per share for a minimum of ten consecutive”

YIELD10 BIOSCIENCE, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“September 25, 2023, Yield10 Bioscience, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until March 25, 2024, to regain compliance. To regain co”

TaoWeave, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“September 21, 2023, Oblong, Inc., a Delaware corporation (the “ Company ”), received written notice (the " Notice ") from the Nasdaq Stock Market, LLC (" Nasdaq ") indicating that the bid price for the Company's common stock (the "Common Stock"), for the last 30 consecutive business days, had closed below the minimum $1.00 per share and, as a result, the Company is not in compliance with the $1.00 minimum bid price requirement for the continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Notice has no effect at this time of the Common Stock, which”

MariaDB plc received a nyse noncompliance notice notice regarding market value (rules 802.01B).

“September 19, 2023, MariaDB plc (the “Company”) received written notice (the “Notice”) from the New York Stock Exchange (“NYSE”) that the Company was not in compliance with the continued listing standard set forth in Section 802.01B of the NYSE’s Listed Company Manual because the average global market capitalization of the Company over a consecutive 30 trading-day period was less than $50 million and, at the same time, the Company’s last reported stockholders’ equity was less than $50 million. In accordance with applicable NYSE procedures, the Company plans to notify the NYSE that it intends t”

Collective Audience, Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“September 19, 2023, to regain compliance with the Rule in accordance with Listing Rule 5810(c)(3)(C). 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 22, 2023 ABRI SPAC I, INC. By: /s/ Jeffrey Tirman Name: Jeffrey Tirman Title: Chief Executive Officer 2”

Fathom Digital Manufacturing Corp received a nyse delisting notice notice regarding other (rules 802.01D).

“A common stock, par value $0.0001 per share (the “Class A common stock”), at a price of $11.50 per share, and listed to trade on the NYSE under the symbol “FATH.WS” (the “Warrants”), and (B) immediately suspend trading in the Warrants due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual, each as of September 22, 2023. The Company does not intend to appeal the NYSE’s determination. Trading in the Company’s Class A common stock will continue on the NYSE under the symbol “FATH”. SIGNATURES Pursuant to the requirements of the Securities Exchang”

Near Intelligence, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(a)(1)).

“September 18, 2023, Near Intelligence, Inc. (the “ Company ”) received a letter from the Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period from August 4, 2023 through September 15, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1). The letter also indicated that the Company will be afforded a period of 180 c”

Near Intelligence, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“September 18, 2023, Near Intelligence, Inc. (the “ Company ”) received a letter from the Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period from August 4, 2023 through September 15, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1). The letter also indicated that the Company will be afforded a period of 180 c”

Latch, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5250(c)(1), 5810(c)(3)(A)).

“September 19, 2023, Latch, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the 30 consecutive trading days prior to the date of the Notice, the Company no longer complies with the minimum closing bid price requirement for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”).”

Vicarious Surgical Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“September 20, 2023, Vicarious Surgical Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the average per share trading price of its Class A common stock (the “Class A common stock”) was below the NYSE’s continued listing standard rule relating to minimum average share price. Rule 802.01C of the NYSE’s Listed Company Manual requires that a company’s common stock trade at a minimum average closing price of $1.00 over a consecutive 30 trading-day period. Pursuant to Section 802.01C, the Company has a period of six months following the receipt o”

Global Gas Corp received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“stating that the market value of listed securities (“MVLS”) of Dune’s Class A common stock for the last 30 consecutive business days (from February 9, 2023 to March 23, 2023), was below the required minimum of $35 million for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Dune had 180 calendar days (or until September 20, 2023) to regain compliance (the “Compliance Period”). The Notification Letter stated that Nasdaq will close the matter and provide written confirmation that Dune has”

Harbor Custom Development, Inc. received a nasdaq noncompliance notice notice regarding audit committee (rules 5605, 5605(c)(4)).

“September 22, 2023, the Company issued a press release announcing the resignation of Mr. Walker, a copy of which is attached as Exhibit 99.1 to this Current Report. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 22, 2023, the Company received a notice (the “Notice”) from The Nasdaq Stock Market LLC (the “Nasdaq”) stating that, as a result of Mr. Walker’s resignation from the Board and the Audit Committee of the Board, the Company is no longer in compliance with Nasdaq Listing Rule 5605. The Notice indicates that, cons”

Aeva Technologies, Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“September 21, 2023, Aeva Technologies, Inc. (the “Company”), received a written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”), as the average closing price of the Company’s common stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice has no immediate impact on the listing of the Company’s common stock, which will remain listed and traded on the NYSE during the cure per”

CuriosityStream Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“September 19, 2023, CuriosityStream Inc. (the “Company”) received written notice (the “Notice”) from the Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock (the “Common Stock”), for the last 31 consecutive business days, had closed below the minimum $1.00 per share and, as a result, the Company is not in compliance with the $1.00 minimum bid price requirement for the continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Notice has no effect at this time on the Common Stock, which continues to trade on t”

Elevation Oncology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“September 19, 2023, Elevation Oncology, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market. Pursuant to N”

Onconetix, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“September 18, 2023, Blue Water Biotech, Inc., a Delaware corporation (the “ Company ”), received a written notice (the “ Notice ”) from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) which sets forth the minimum bid price requirement for continued listing on the Nasdaq Capital Market (the “ Minimum Bid Requirement ”) as the bid price of the Company’s common stock, par value $0.00001 per share (the “ Common Stock ”), had closed below $1.00 per share for 30 cons”

Triller Group Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“September 20, 2023, AGBA Group Holding (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s ordinary shares, par value $0.001 per share (the “Ordinary Shares”), for the last 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share (the “M”

American Bitcoin Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“September 19, 2023, to regain compliance with the Equity Rule. However, the Staff indicated in the Determination Letter that, pursuant to Listing Rule 5810(d)(2), this deficiency serves as an additional and separate basis for delisting, and as such, the Company should address its non-compliance with the Equity Rule before a Hearings Panel (the “Panel”) if it appeals the Staff’s determination. The Company believes that its ongoing and previously announced transactions with Gryphon Digital Mining, Inc. and MJ Acquisition Corp., which transactions will include a reverse stock split in the Company”

Lovesac Co received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“September 18, 2023, the Company received a written notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq’s Listing Rule 5250(c)(1) because the Company did not timely file its Quarterly Report. Under Nasdaq rules, the Company now has 60 calendar days (until November 17, 2023) to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, Nasdaq can grant an exception of up to 180 calendar days from the Quarterly Report’s original due date, which 180-day period would end on March 6, 2024, to regain compliance”

AIRWA INC. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1), 5810(b)).

“September 18, 2023, Connexa Sports Technologies Inc. (the “ Company ”) received a letter (“ Letter ”) from the Listing Qualifications Department of The Nasdaq Capital Market (“ Nasdaq ”) indicating that the Company’s failure to file its Quarterly Report on Form 10-Q for the period ended July 31, 2023 (the “ Form 10-Q ”), in violation of the Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “ Rule ”), serves as an additional basis for delisting the Company’s securities from Nasdaq based on Listing Rule 5810(b). According to the Letter, the Nasdaq Hearings Panel (”

Alzamend Neuro, Inc. received a nasdaq extension granted notice regarding minimum bid price.

“September 22, 2023, the Company issued a press release to announce the extension granted by the Nasdaq Hearings Panel. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. In accordance with General Instruction B.2 of Form 8-K, the information under this item shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific referen”

ATLANTIC INTERNATIONAL CORP. received a nasdaq deficiency notice notice regarding other (rules 5550(a)(4)).

“September 8, 2023, SeqLL Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) regarding compliance with Nasdaq Listing Rule 5550(a)(4) (the “Rule”), which requires the Company to have a minimum of 500,000 publicly held shares, exclusive of shares held by officers, directors and 10% stockholders. The letter from Nasdaq indicated that according to its calculations, as of September 7, 2023, the Company no longer meets the requirements of the Rule. On September 18, 2023, the Company received a letter from the Listing Qualifications”

Matinas BioPharma Holdings, Inc. received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v), 1009).

“September 21, 2023, Matinas Biopharma Holdings, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the NYSE American LLC (the “NYSE American” or the “Exchange”) indicating that the Company is not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide due to its shares of common stock selling for a substantial period of time at a low price per share, which NYSE American determined to be a 30 trading day average price of less than $0.20 per share. The Letter has no immediate effect on the listing or tr”

Galera Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“September 22, 2023, Galera Therapeutics, Inc. (the “Company”) received two written notices (the “Notices”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that (i) the Company is no longer in compliance with the minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “Minimum MVLS Requirement”) and (ii) for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), had closed bel”

Galera Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“September 22, 2023, Galera Therapeutics, Inc. (the “Company”) received two written notices (the “Notices”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that (i) the Company is no longer in compliance with the minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “Minimum MVLS Requirement”) and (ii) for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), had closed bel”

Invitae Corp received a nyse noncompliance notice notice regarding minimum bid price (rules 802.01C).

“September 20, 2023, Invitae Corporation (the "Company") received a notice (the "Notice") from the New York Stock Exchange (the “NYSE”) that it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE Listed Company Manual ("Section 802.01C") because the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period. In accordance with Section 802.01C, the Company notified the NYSE of its intent to regain compliance with the minimum share price requirement. The Company may regain compliance at”

Workhorse Group Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“September 22, 2023, Workhorse Group Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of Nasdaq Stock Market (“Nasdaq”) indicating that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive trading days, the Company was no longer in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice has no immediate effect on the listing of the Company’s com”

Veradigm Inc. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“September 20, 2023, the Company received notice (the “Delisting Notice”) from Nasdaq that the Company's shares would be delisted. The Company intends to appeal the determination made by Nasdaq pursuant to the procedures set forth in the Listing Rules. As previously disclosed, the Listing Rules provide that the Company may request a hearing (the “Hearing Request”) before a Nasdaq Hearings Panel (the “Panel”) and that the request will temporarily stay any suspension or delisting action for 22 days from the date of the Delisting Notice. Further, the Listing Rules provide that, in its Hearing Requ”

ProSomnus, Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(2)(C), 5810(c)(3)(D)).

“September 18, 2023, the Company received a notification letter (the “Notification Letter”) from Nasdaq that the Company is not in compliance with the minimum Market Value of Publicly Held Shares (the “MVPHS”) set forth in Nasdaq Listing Rule 5450(b)(2)(C) for continued listing on Nasdaq. Nasdaq Listing Rule 5450(b)(2)(C) requires the minimum MVPHS of $15,000,000 (the “MVPHS Requirement”), and Nasdaq Listing Rule 5810(c)(3)(D) provides that a failure to meet the minimum MVPHS Requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the MVPHS of the C”

KIDPIK CORP. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“September 19, 2023, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to March 18, 2024, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company will continue to monitor the closing bid price of its Common Stock and will, if necessary, implement a reverse stock split of its outstanding securities, to regain compliance with the Minimum Bid Price Requirement. The stockholders of the Company, at the June 19, 2023, annual meeting of stockholders previously approved an amend”

FaZe Holdings Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“notifying the Company that the Company’s common stock no longer met the Nasdaq requirement for continued listing on The Nasdaq Capital Market to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement"). The Company was provided until September 19, 2023, to regain compliance with the continued”

Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“August 17, 2023, the Company received a staff deficiency notice from Nasdaq indicating that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1), which requires that a listed company’s stockholders’ equity be at least $2,500,000 (the “Minimum Stockholders’ Equity Requirement”). On September 21, 2023, the Company received a written notice (the “Notice”) from the Nasdaq staff confirming the staff’s determination that the Company had, a”

Vivos Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“September 21, 2023, the Company received a written notice (the “Notice”) from the Nasdaq staff confirming the staff’s determination that the Company had, as of the date of the Notice, failed to meet the Minimum Bid Requirement and that Nasdaq would commence delisting proceedings against the Company. The Company may appeal the Nasdaq staff’s determination, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, no later than 4:00 pm Eastern Time on September 28, 2023. The Company plans to timely file such an appeal and request a hearing (the “Hearing”) before a Nasdaq Heari”

Processa Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“September 19, 2023, the Company received a letter from the Staff notifying that the Company is eligible for a second 180-day period, or until March 18, 2024 (the “Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the minimum bid price requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure”

Processa Pharmaceuticals, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

“March 22, 2023, Processa Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). On September 19, 2023, the Company received a letter from the Staff notifying that the Company is eligible fo”

SHINECO, INC. received a nasdaq extension granted notice regarding minimum bid price.

“September 19, 2023, the Company received notice from Nasdaq indicating that, while the Company has not regained compliance with the minimum bid price requirement, staff of Nasdaq has determined that the Company is eligible for an additional 180-day period, or until March 18, 2024, to regain compliance. Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of our publicly held shares and all other applicable requirements for initial listing on the Capital Market, with the exception of the bid price requirement, and (ii) the Company’s writt”

Rose Hill Acquisition Corp received a nasdaq delisting notice notice regarding other (rules 5550(a)(4), 5550(a)(3)).

“July 26, 2023, Rose Hill Acquisition Corporation (the “Company”) received a delisting determination letter (the “Determination Letter”) from the staff (“Staff”) of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that (i) it had not regained compliance with Nasdaq Listing Rule 5550(a)(4) requiring a minimum of 500,000 publicly held shares by the extension deadline of July 24, 2023, which was granted to the Company by the Staff pursuant to the Company’s plan of compliance submitted to the Staff on February 7, 2023 and later supplemented on”